Read more

October 11, 2019
3 min watch
Save

VIDEO: Teprotumumab reduces double vision in phase 3 study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — At the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting, Raymond Douglas, MD, PhD, of Cedars-Sinai Medical Center, discusses new data from the phase 3 OPTIC confirmatory clinical trial.